AU2018385724B2 - Triazolobenzazepines as vasopressin V1a receptor antagonists - Google Patents

Triazolobenzazepines as vasopressin V1a receptor antagonists Download PDF

Info

Publication number
AU2018385724B2
AU2018385724B2 AU2018385724A AU2018385724A AU2018385724B2 AU 2018385724 B2 AU2018385724 B2 AU 2018385724B2 AU 2018385724 A AU2018385724 A AU 2018385724A AU 2018385724 A AU2018385724 A AU 2018385724A AU 2018385724 B2 AU2018385724 B2 AU 2018385724B2
Authority
AU
Australia
Prior art keywords
triazolo
chloro
trans
dihydro
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018385724A
Other languages
English (en)
Other versions
AU2018385724A1 (en
Inventor
Ferenc BASKA
Imre Bata
Éva BOZÓ
Krisztina SZONDINÉ KORDÁS
Krisztina Vukics
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of AU2018385724A1 publication Critical patent/AU2018385724A1/en
Application granted granted Critical
Publication of AU2018385724B2 publication Critical patent/AU2018385724B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08Oxygen atoms
    • C07D223/10Oxygen atoms attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2018385724A 2017-12-15 2018-12-14 Triazolobenzazepines as vasopressin V1a receptor antagonists Active AU2018385724B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1700521 2017-12-15
HU1700521A HU231206B1 (hu) 2017-12-15 2017-12-15 Triazolobenzazepinek
PCT/IB2018/060077 WO2019116324A1 (en) 2017-12-15 2018-12-14 Triazolobenzazepines as vasopressin v1a receptor antagonists

Publications (2)

Publication Number Publication Date
AU2018385724A1 AU2018385724A1 (en) 2020-07-09
AU2018385724B2 true AU2018385724B2 (en) 2023-05-25

Family

ID=89992589

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018385724A Active AU2018385724B2 (en) 2017-12-15 2018-12-14 Triazolobenzazepines as vasopressin V1a receptor antagonists

Country Status (23)

Country Link
US (1) US11298363B2 (https=)
EP (1) EP3724192B1 (https=)
JP (1) JP7428647B2 (https=)
KR (1) KR102719165B1 (https=)
CN (1) CN111479813B (https=)
AR (1) AR113933A1 (https=)
AU (1) AU2018385724B2 (https=)
BR (1) BR112020011880A2 (https=)
CA (1) CA3085562A1 (https=)
CL (1) CL2020001564A1 (https=)
CU (1) CU24630B1 (https=)
EA (1) EA202091344A1 (https=)
HU (1) HU231206B1 (https=)
IL (1) IL275084B2 (https=)
JO (1) JOP20200149B1 (https=)
MX (1) MX2020006204A (https=)
PE (1) PE20210671A1 (https=)
PH (1) PH12020500548A1 (https=)
SG (1) SG11202005299VA (https=)
TN (1) TN2020000083A1 (https=)
TW (1) TWI826406B (https=)
UA (1) UA129516C2 (https=)
WO (1) WO2019116324A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物
WO2022018121A1 (en) * 2020-07-23 2022-01-27 F. Hoffmann-La Roche Ag Cyclohexyl substituted triazoles as vasopressin receptor v1 a antagonists
TWI804119B (zh) * 2020-12-21 2023-06-01 大陸商上海濟煜醫藥科技有限公司 三氮唑類三并環衍生物及其製備方法和應用
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
WO2023164710A1 (en) * 2022-02-28 2023-08-31 The Trustees Of Columbia University In The City Of New York Avpr1a blockade to reduce social isolation-induced anxiety in females
US12310974B1 (en) 2023-12-19 2025-05-27 Samuel Aballea Method of treating post-traumatic stress disorder with carpipramine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074291A1 (en) * 2003-02-19 2004-09-02 Pfizer Limited Triazole compounds useful in therapy
WO2005068466A1 (en) * 2004-01-13 2005-07-28 Pfizer Limited Compounds useful in therapy
WO2008052628A1 (de) * 2006-11-03 2008-05-08 Merck Patent Gmbh Triaza-benzo[e]azulenderivate zur behandlung von tumoren
WO2011131596A1 (en) * 2010-04-21 2011-10-27 F. Hoffmann-La Roche Ag Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes as vasopressin v1a receptor antagonists
WO2014048945A1 (de) * 2012-09-28 2014-04-03 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 5-aryl-triazolo-azepine
CN106349241A (zh) * 2015-07-15 2017-01-25 上海翰森生物医药科技有限公司 具有hsp90抑制活性的三唑衍生物及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0382185B1 (en) 1989-02-10 1994-06-15 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
FR2679903B1 (fr) 1991-08-02 1993-12-03 Elf Sanofi Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
EP1097920B1 (en) 1993-07-21 2004-09-22 Yamanouchi Pharmaceutical Co. Ltd. Intermediate for condensed benzazepine derivatives
ES2284741T3 (es) 1994-06-15 2007-11-16 Otsuka Pharmaceutical Company, Limited Derivados de benzoheterociclicos utilizados como moduladores de vasoprsinao de oxitocina.
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
SK16242002A3 (sk) 2000-05-19 2003-04-01 Merck Patent Gmbh Derivát triazolu a farmaceutický prostriedok, ktorý ho obsahuje
US7001898B2 (en) 2000-07-05 2006-02-21 Ortho-Mcneil Pharmaceutical, Inc. Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
US7056910B2 (en) 2000-11-28 2006-06-06 Astellas Pharma Inc. 1,4,5.6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof
MXPA04003358A (es) 2001-10-12 2004-07-08 Serenix Pharmaceuticals Llc Antagonistas de vasopresina v1a de ?-lactamilo.
JP2005104838A (ja) 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
KR100750028B1 (ko) * 2003-02-19 2007-08-16 화이자 인코포레이티드 치료에 유용한 트리아졸 화합물
GB0325021D0 (en) * 2003-10-27 2003-12-03 Pfizer Ltd Therapeutic combinations
EA010132B1 (ru) 2003-12-22 2008-06-30 Пфайзер Инк. Производные триазола в качестве антагонистов вазопрессина
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
CA2578370A1 (en) 2004-08-25 2006-03-02 Pfizer Inc. Triazolobenzodiazepines and their use as vasopressin antagonists
CA2593044A1 (en) 2004-12-31 2006-07-13 Abbott Gmbh & Co. Kg Substituted oxindole derivatives, medicaments containing said derivatives and use thereof
CA2602194A1 (en) 2005-03-24 2006-09-28 Abbott Gmbh & Co. Kg Substituted oxindol derivatives, drugs containing said derivatives and the use thereof
ES2434467T3 (es) 2005-05-13 2013-12-16 Lexicon Pharmaceuticals, Inc. Compuestos multicíclicos y métodos para su uso
CA2615726C (en) 2005-07-14 2014-05-27 Caterina Bissantz Indol-3-yl-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
KR100984893B1 (ko) 2005-07-21 2010-10-01 에프. 호프만-라 로슈 아게 V1a 수용체 길항제로서의인돌-3-일-카보닐-피페리딘-벤조이미다졸 유도체
EP2392571A3 (en) 2005-07-29 2012-03-14 F. Hoffmann-La Roche AG Indol-3-yl-carbonyl-piperidin and piperazin derivatives
JP2010517966A (ja) 2007-02-01 2010-05-27 グラクソ グループ リミテッド 摂食障害の処置のための1−オキサ−3−アザスピロ(4.5)デカン−2−オンおよび1−オキサ−3,8−ジアザスピロ(4.5)デカン−2−オン誘導体
TWI459947B (zh) 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
BRPI0922303B1 (pt) 2008-11-28 2019-11-12 Hoffmann La Roche arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos, seu processo de preparação, composição farmacêutica que os compreende e uso
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
TW201103907A (en) 2009-03-20 2011-02-01 Lundbeck & Co As H Amide derivatives as neuropeptide Y5 receptor ligands
SG10201406839VA (en) 2009-10-26 2014-12-30 Otsuka Pharma Co Ltd Benzazepine compound
GB201004677D0 (en) 2010-03-19 2010-05-05 Vantia Ltd New salt
US8461151B2 (en) 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8513238B2 (en) 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
EP2569280B1 (en) 2010-05-11 2015-02-25 Sanofi Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
US20130237530A1 (en) * 2010-11-15 2013-09-12 Agenebio, Inc. Benzodiazepine derivatives, compositions and methods for treating cognitive impairment
CN105263910A (zh) 2013-02-18 2016-01-20 斯克利普斯研究所 具有治疗潜力的血管加压素受体调节剂
EP3230281B1 (en) 2014-12-09 2021-05-26 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
RU2017131562A (ru) 2015-02-27 2019-03-27 Версеон Корпорейшн Замещенные пиразольные соединения как ингибиторы сериновых протеаз
WO2017007756A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
AR108263A1 (es) 2016-05-03 2018-08-01 Bayer Pharma AG Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
EP3452472A1 (en) 2016-05-03 2019-03-13 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074291A1 (en) * 2003-02-19 2004-09-02 Pfizer Limited Triazole compounds useful in therapy
WO2005068466A1 (en) * 2004-01-13 2005-07-28 Pfizer Limited Compounds useful in therapy
WO2008052628A1 (de) * 2006-11-03 2008-05-08 Merck Patent Gmbh Triaza-benzo[e]azulenderivate zur behandlung von tumoren
WO2011131596A1 (en) * 2010-04-21 2011-10-27 F. Hoffmann-La Roche Ag Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes as vasopressin v1a receptor antagonists
WO2014048945A1 (de) * 2012-09-28 2014-04-03 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 5-aryl-triazolo-azepine
CN106349241A (zh) * 2015-07-15 2017-01-25 上海翰森生物医药科技有限公司 具有hsp90抑制活性的三唑衍生物及其制备方法和应用

Also Published As

Publication number Publication date
CA3085562A1 (en) 2019-06-20
KR20200100111A (ko) 2020-08-25
UA129516C2 (uk) 2025-05-21
IL275084A (en) 2020-07-30
CU20200048A7 (es) 2021-03-11
EP3724192A1 (en) 2020-10-21
MX2020006204A (es) 2020-08-27
JP7428647B2 (ja) 2024-02-06
US11298363B2 (en) 2022-04-12
CU24630B1 (es) 2022-12-12
SG11202005299VA (en) 2020-07-29
EA202091344A1 (ru) 2020-09-09
JOP20200149B1 (ar) 2022-10-30
TWI826406B (zh) 2023-12-21
BR112020011880A2 (pt) 2020-11-24
AU2018385724A1 (en) 2020-07-09
WO2019116324A1 (en) 2019-06-20
TW201938170A (zh) 2019-10-01
KR102719165B1 (ko) 2024-10-17
JP2021506821A (ja) 2021-02-22
EP3724192B1 (en) 2022-08-03
TN2020000083A1 (en) 2022-01-06
CL2020001564A1 (es) 2020-11-06
JOP20200149A1 (ar) 2020-06-10
HUP1700521A2 (en) 2019-06-28
PH12020500548A1 (en) 2021-01-25
CN111479813B (zh) 2023-03-21
IL275084B2 (en) 2023-06-01
CN111479813A (zh) 2020-07-31
HU231206B1 (hu) 2021-10-28
PE20210671A1 (es) 2021-04-05
AR113933A1 (es) 2020-07-01
US20210260072A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
AU2018385724B2 (en) Triazolobenzazepines as vasopressin V1a receptor antagonists
CA2997382C (en) Substituted amino triazoles useful as human chitinase inhibitors
ES2739697T3 (es) Nuevos compuestos y derivados de espiro[3H-indol-3,2-pirrolidin]-2(1H)-ona como inhibidores de MDM2-p53
CN113234036B (zh) Nmda受体拮抗剂及其用途
EP2569310A1 (en) Morpholine compounds as mineralocorticoid receptor antagonists
TW201132642A (en) Diaza-spiro[5.5]undecanes
EP2044057A2 (fr) Dérivés d'urées de piperidine ou pyrrolidine, leur préparation et leur application en thérapeutique
JP3026945B2 (ja) 3−アザ及び3−オキサピペリドンタキキニン拮抗薬
WO2019116325A1 (en) Tricyclic compounds as vasopressin v1a receptor antagonists
CN112313220B (zh) Pd-l1拮抗剂化合物
JP5559336B2 (ja) 二環式へテロ環及びccr2レセプターアンタゴニストとしてのそれらの使用
CN105793266B (zh) 螺-噁唑酮
DE602004003914T2 (de) Für die therapie geeignete triazolverbindungen
WO2025209533A1 (zh) 一种pan-RAS抑制剂化合物
KR20220042379A (ko) 키티나제 억제제로서 유용한 치환된 아미노 트리아졸
RU2414456C2 (ru) N-дигидроксиалкилзамещенные производные 2-оксоимидазола
SK113399A3 (en) Quinoxalinediones
OA19571A (en) Triazolobenzazepines as vasopressin V1a receptor antagonists.
EA042383B1 (ru) Триазолобензазепины как антагонисты v1a рецепторов вазопрессина
HK1223922B (zh) 螺-恶唑酮

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)